Home » Note to Subscribers

Note to Subscribers

Aug 22, 2012
Premium

Clinical Sequencing News will not publish next week, Wed., Aug. 29. The next issue will go out to subscribers on Sept. 5.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Related Articles

Jul 29, 2014

Note to Readers

Premium
Oct 01, 2014

Project Aims to Collect Data on Pathogenic Variants and VUS from Hereditary Cancer Panels

Premium
Aug 26, 2014

ABRF Assesses NGS Platforms, Library Prep, Bioinformatics in Effort to Create RNA-seq Standards

Premium
Nov 12, 2014

Researchers Develop Plan to Tackle Reimbursement Challenges for NGS Tests

Premium
Sep 17, 2014

Mt. Sinai to Open Clinical NGS Lab; Aims to Sequence 1 Million Individuals in Resilience Project

Premium
Nov 05, 2014

Sequenom Looking to Quest Deal and VisibiliT to Spur Growth

Premium

The Scan

This Week in PLOS

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

Things Not Found

With a new collection, PLOS highlights negative results it has published.

Is the Sequencer Half Full or Half Empty?

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

Packs a Punch

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.

What's Popular?

In Clinical Sequencing

  1. AGBT: WashU Applies Genomic Testing to Predict Cancer Relapse, Drug Response, Vaccine Epitopes

    Premium

  2. U of Cambridge, Genomics England, Illumina to Sequence 10,000 Genomes from Rare Disease Patients

  3. Personal Genome Diagnostics, Blueprint Medicines to ID Novel Drug Targets in Cancer

  4. Personal Genome Diagnostics Aims for FDA Clearance of NGS-based Cancer Products

    Premium

  5. Q&A: Matt Posard on Illumina's Clinically Focused Business Unit

    Premium

Sponsorships

Privacy Policy.  Copyright © 2015 Genomeweb LLC.  All Rights Reserved.